Medical Writers News Hubb
Advertisement Banner
  • Home
  • News
  • Papers
  • Contact
No Result
View All Result
  • Home
  • News
  • Papers
  • Contact
No Result
View All Result
Wellnessnewshubb
No Result
View All Result
Home News

RQM+ acquires Jordi Labs | Medical Design & Outsourcing

admin by admin
September 8, 2022
in News


RQM+ has purchased Jordi Labs, the two companies said today.

Terms of the deal were not disclosed.

Jordi Labs provides chemical characterization, complex product deformulation and contaminant and failure investigations for medtech manufacturers.

“As the only medtech service provider rooted in almost 40 years of regulatory strategy, RQM+ is proud to now offer proprietary testing services for extractables and leachables, which gives our customers the fastest path to regulatory approvals,” RQM+ CEO Margaret Keegan said in a news release. “We are relentlessly focused on being the best at every service we provide to medtech manufacturers. Jordi’s world-leading testing services will help us maintain our uncompromising quality standards at every stage as we grow into a one-stop-shop to expedite patient access to life-improving technologies.”

Formerly known as Regulatory and Quality Solutions, Monroeville, Pennsylvania-based RQM+ has been a portfolio company of Chicago-based private equity firm Linden Capital Partners since August 2021. RQM+ called itself the largest medical device- and diagnostics-focused regulatory and quality consulting company in the world following its 2020 acquisition of Maetrics.

“We are delighted to now be a part of the RQM+ solution that brings customers to market faster with our unmatched track record of rapid testing results that satisfy the stringent requirements of regulators globally,” Jordi Labs President Mark Jordi said in the news release. “Joining RQM+ will enable me to focus on what I love – developing groundbreaking technology that ensures patient safety by setting new standards for extractables and leachables testing.”

In March, RQM+ named Keegan as CEO to replace co-founder Maria Fagan, who retired as CEO but joined the board as vice chair. Keegan was previously chief operating officer of PRA Health Sciences (now ICON) and served as president of clinical development for IQVIA before that.



Source link

Previous Post

Recent developments in the use of nanoparticles to deliver drugs to the brain via intranasal administration

Next Post

Biosynthetic proteins show promise as SARS-CoV-2 antivirals targeting spike protein

Next Post

Biosynthetic proteins show promise as SARS-CoV-2 antivirals targeting spike protein

Recommended

Glowing nanoparticles enhance at-home COVID-19 test sensitivity

7 months ago

Poor eating habits of university students can contribute to future health issues

4 months ago

Concern over two cases of monkeypox-related neurological complications in the U.S.

1 year ago

Radiated, ‘humanized’ mice offer insights into implant rejection

2 months ago

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

9 months ago

5 questions device manufacturers must ask lab testing partners

4 months ago
Medical-Writers-(-white-)

© Medical Writers News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Papers
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Papers
  • Contact

© 2022 Medical Writers News Hubb All rights reserved.